Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Highlights•The fundamentals of radiotheranostics, established therapies, and key clinical
studies.•Future developments: new targets, new radionuclides, new platforms, and …

Background High-risk localised prostate cancer (HRCaP) has high rates of biochemical
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …

Background De novo oligometastatic prostate cancer (omPCa) on prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and …

Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most
prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this …

PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …

Radionuclide therapy using the small molecule PSMA bound to the beta-emitting
radionuclide, Lutetium-177 (177 Lu-PSMA) has demonstrated efficacy and survival benefit …

β-emitting 177Lu targeting prostate-specific membrane antigen (PSMA) is an approved
treatment option for metastatic castration-resistant prostate cancer. Data on its long-term …

Despite significant advances in therapeutic developments for prostate cancer over the last 2
decades, metastatic prostate cancer remains a lethal disease. Prostate-specific membrane …

Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine
involving the use of the same or similar radiopharmaceutical agents for the diagnosis and …